BidaskClub downgraded shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) from a buy rating to a hold rating in a research note released on Thursday.
Several other analysts have also commented on SPPI. HC Wainwright restated a buy rating on shares of Spectrum Pharmaceuticals in a research report on Friday, November 3rd. B. Riley started coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, December 18th. They set a buy rating and a $26.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Spectrum Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, January 2nd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $22.83.
Spectrum Pharmaceuticals (NASDAQ SPPI) traded down $0.05 during mid-day trading on Thursday, reaching $20.46. 850,600 shares of the company traded hands, compared to its average volume of 947,004. The firm has a market capitalization of $2,060.00, a price-to-earnings ratio of -21.24 and a beta of 1.64. The company has a current ratio of 5.04, a quick ratio of 4.89 and a debt-to-equity ratio of 0.33. Spectrum Pharmaceuticals has a 52 week low of $5.47 and a 52 week high of $23.50.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.